Claire Flaujac
Overview
Explore the profile of Claire Flaujac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raulet-Bussian C, Launois A, Perez F, Martin-Toutain I, Goubeau L, Magnian B, et al.
Int J Lab Hematol
. 2025 Jan;
PMID: 39844580
No abstract available.
2.
Stepanian A, Fischer F, Flaujac C, Eschwege V, Delassasseigne C, Leflem L, et al.
Platelets
. 2024 Nov;
35(1):2427745.
PMID: 39555668
Light transmission aggregometry (LTA) is a method used to investigate platelet functions in platelet-rich plasma (PRP), notably when screening for platelet disorders. Various national guidelines and recommendations help in setting...
3.
Arocas V, Venisse L, Boulaftali Y, Loyau S, Flaujac C, de Raucourt E, et al.
Thromb Res
. 2024 Oct;
243:109174.
PMID: 39378567
No abstract available.
4.
Flaujac C, Delassasseigne C, Hurtaud-Roux M, Delahousse B, Boissier E, Desconclois C
Semin Thromb Hemost
. 2024 Aug;
PMID: 39214147
Preanalytical sample management is critical for a proper assessment of hemostasis parameters, and may differ depending on prescribed tests or additional tests considered to be necessary after initial results. Although...
5.
Launois A, Martin-Toutain I, Devaux F, Lambert J, Longval T, Merabet F, et al.
Ann Biol Clin (Paris)
. 2024 Aug;
82(3):294-307.
PMID: 39150152
Emicizumab is a bispecific antibody that mimics the function of factor VIII (FVIII) and is indicated for prophylactic use in patients with congenital hemophilia A with or without inhibitors. Acquired...
6.
Ajzenberg N, Longrois D, Faille D, de Tymowski C, de Raucourt E, Boudaoud L, et al.
J Thromb Haemost
. 2024 Aug;
22(11):3048-3058.
PMID: 39128655
Background: Preoperative identification of patients with hemostasis abnormalities leading to an increased bleeding risk is based on routine hemostasis tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet...
7.
Launois A, Zia Chahabi S, Devaux F, Amouroux I, Flaujac C
Blood Coagul Fibrinolysis
. 2023 Dec;
35(1):14-22.
PMID: 38051662
Laboratory compliance implies to correlate instruments for coagulation parameter with a wide range of measure using patient samples or commercialized sets of frozen plasmas. The aim of this study was...
8.
Lasne D, Toussaint-Hacquard M, Delassasseigne C, Bauters A, Flaujac C, Savard P, et al.
Thromb Haemost
. 2023 Jun;
123(12):1105-1115.
PMID: 37321244
Background: The presence of dextran sulfate (DS) in reagents and the type of blood collection tube (citrate/citrated-theophylline-adenosine-dipyridamole [CTAD]) can lead to discrepancies between unfractionated heparin (UFH) anti-Xa levels. Objectives: To...
9.
de Mazancourt P, Quelin F, Flaujac C, de Raucourt E, Guillet B, Bauduer F, et al.
Haemophilia
. 2023 May;
29(4):1113-1120.
PMID: 37252892
Introduction: Dominant-negative effects have been described for 10 F11 variants in the literature. Aim: The current study aimed at identifying putative dominant-negative F11 variants. Material And Methods: This research consisted...
10.
Hugon-Rodin J, Carriere C, Claeyssens S, Trillot N, Drillaud N, Biron-Andreani C, et al.
J Thromb Haemost
. 2023 May;
21(8):2126-2136.
PMID: 37172732
Background: Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited. Objectives: We aimed to determine the prevalence...